Steven M. Bray

2.4k total citations
19 papers, 1.6k citations indexed

About

Steven M. Bray is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Steven M. Bray has authored 19 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in Steven M. Bray's work include Cancer Genomics and Diagnostics (5 papers), Genetics and Neurodevelopmental Disorders (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Steven M. Bray is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Genetics and Neurodevelopmental Disorders (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Steven M. Bray collaborates with scholars based in United States, South Korea and Canada. Steven M. Bray's co-authors include Stephen T. Warren, Hubert Amrein, Natasha Thorne, Tao Wang, Zigang Li, Peng Jin, Daniela C. Zarnescu, Chuan He, Shuang Chang and Stephen Wooding and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Steven M. Bray

18 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven M. Bray United States 14 899 683 601 326 231 19 1.6k
Yves Grau France 20 330 0.4× 1.1k 1.6× 970 1.6× 60 0.2× 137 0.6× 26 1.7k
Tong‐Wey Koh United States 13 412 0.5× 1.8k 2.6× 1.1k 1.8× 73 0.2× 149 0.6× 17 2.6k
Frances Hannan United States 17 307 0.3× 751 1.1× 970 1.6× 73 0.2× 256 1.1× 21 1.8k
Hiroshi Ishimoto Japan 20 361 0.4× 367 0.5× 991 1.6× 66 0.2× 351 1.5× 28 1.3k
Thomas O. Auer Switzerland 19 436 0.5× 771 1.1× 516 0.9× 47 0.1× 218 0.9× 29 1.5k
Soohong Min United States 16 418 0.5× 352 0.5× 878 1.5× 43 0.1× 392 1.7× 19 1.6k
Mattias Alenius Sweden 15 618 0.7× 1.1k 1.5× 1.2k 2.0× 36 0.1× 327 1.4× 22 2.4k
Jacob A. Berry United States 15 339 0.4× 282 0.4× 606 1.0× 177 0.5× 97 0.4× 25 1.2k
Erroll H. Rueckert United States 7 267 0.3× 375 0.5× 540 0.9× 45 0.1× 136 0.6× 8 943
Thomas Hendel Germany 9 321 0.4× 358 0.5× 984 1.6× 185 0.6× 190 0.8× 11 1.2k

Countries citing papers authored by Steven M. Bray

Since Specialization
Citations

This map shows the geographic impact of Steven M. Bray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Bray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Bray more than expected).

Fields of papers citing papers by Steven M. Bray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Bray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Bray. The network helps show where Steven M. Bray may publish in the future.

Co-authorship network of co-authors of Steven M. Bray

This figure shows the co-authorship network connecting the top 25 collaborators of Steven M. Bray. A scholar is included among the top collaborators of Steven M. Bray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven M. Bray. Steven M. Bray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Ly, Reynold C., Jennelle C. Hodge, Amy M. Breman, et al.. (2023). Computational pharmacogenotype extraction from clinical next-generation sequencing. Frontiers in Oncology. 13. 1199741–1199741. 8 indexed citations
3.
Radovich, Milan, Jeffrey P. Solzak, Bradley A. Hancock, et al.. (2022). Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 28(15). 3235–3241. 21 indexed citations
4.
Ly, Reynold C., Victoria M. Pratt, Bryan P. Schneider, et al.. (2022). Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing. Journal of Molecular Diagnostics. 24(6). 576–585. 10 indexed citations
5.
Bernard, Philip S., Whitney Wooderchak‐Donahue, Mei Wei, et al.. (2021). Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer. Cancers. 13(6). 1219–1219. 1 indexed citations
6.
Liu, Jiangang, Yong Beom Cho, Hye Kyung Hong, et al.. (2020). Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis. Scientific Reports. 10(1). 10725–10725. 23 indexed citations
7.
Vuaroqueaux, Vincent, Swee Seong Wong, Jason C. Ting, et al.. (2020). Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma. Communications Biology. 3(1). 367–367. 13 indexed citations
8.
Donoho, Gregory P., Philip W. Iversen, Youyan Zhang, et al.. (2017). Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. Clinical Cancer Research. 23(18). 5547–5560. 39 indexed citations
9.
Liu, Weihua, Zhenyu Yan, Candice L. Horn, et al.. (2015). Abstract 4925: Liquid biopsy using the ion AmpliSeq v2 cancer panel. Cancer Research. 75(15_Supplement). 4925–4925. 1 indexed citations
10.
Wang, Tao, Steven M. Bray, & Stephen T. Warren. (2012). New perspectives on the biology of fragile X syndrome. Current Opinion in Genetics & Development. 22(3). 256–263. 96 indexed citations
11.
Bray, Steven M., et al.. (2011). Molecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective. Annual Review of Pathology Mechanisms of Disease. 7(1). 219–245. 404 indexed citations
12.
Collins, Stephen C., Steven M. Bray, Joshua A. Suhl, et al.. (2010). Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males. American Journal of Medical Genetics Part A. 152A(10). 2512–2520. 82 indexed citations
13.
Bray, Steven M., Jennifer G. Mullé, Anne Dodd, et al.. (2010). Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population. Proceedings of the National Academy of Sciences. 107(37). 16222–16227. 81 indexed citations
14.
Chang, Shuang, Steven M. Bray, Zigang Li, et al.. (2008). Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nature Chemical Biology. 4(4). 256–263. 214 indexed citations
15.
Thorne, Natasha, et al.. (2004). Taste Perception and Coding in Drosophila. Current Biology. 14(12). 1065–1079. 315 indexed citations
16.
Amrein, Hubert & Steven M. Bray. (2003). Bitter-Sweet Solution in Taste Transduction. Cell. 112(3). 283–284. 15 indexed citations
17.
Bray, Steven M. & Hubert Amrein. (2003). A Putative Drosophila Pheromone Receptor Expressed in Male-Specific Taste Neurons Is Required for Efficient Courtship. Neuron. 39(6). 1019–1029. 213 indexed citations
18.
McLaughlin, Joseph N., Craig D. Thulin, Steven M. Bray, et al.. (2002). Regulation of Angiotensin II-induced G Protein Signaling by Phosducin-like Protein. Journal of Biological Chemistry. 277(38). 34885–34895. 16 indexed citations
19.
Martin, Mickey M., Barry M. Willardson, Gregory F. Burton, et al.. (2001). Human Angiotensin II Type 1 Receptor Isoforms Encoded by Messenger RNA Splice Variants Are Functionally Distinct. Molecular Endocrinology. 15(2). 281–293. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026